EP0966522A1 - Lignee cellulaire humaine du foie - Google Patents

Lignee cellulaire humaine du foie

Info

Publication number
EP0966522A1
EP0966522A1 EP98916819A EP98916819A EP0966522A1 EP 0966522 A1 EP0966522 A1 EP 0966522A1 EP 98916819 A EP98916819 A EP 98916819A EP 98916819 A EP98916819 A EP 98916819A EP 0966522 A1 EP0966522 A1 EP 0966522A1
Authority
EP
European Patent Office
Prior art keywords
cells
hepatocytes
hepz
cell line
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98916819A
Other languages
German (de)
English (en)
Inventor
Michael Strauss
Ira Kirillowa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
HepaVec AG fur Gentherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HepaVec AG fur Gentherapie filed Critical HepaVec AG fur Gentherapie
Publication of EP0966522A1 publication Critical patent/EP0966522A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the invention relates to a new human liver cell line that can be used for toxicological, physiological and particularly gene therapy studies. Areas of application are molecular biology, medicine and the pharmaceutical industry.
  • Gene therapy for diseases of the liver is an important goal of molecular medicine, since a large number of genetic diseases, but also infectious and tumor diseases, originate in this organ.
  • the complex route of ex vivo gene therapy has been opened up internationally, in which part of the liver is removed and the cells isolated therefrom are treated in the cell culture with the therapeutic gene and then transplanted back into the liver.
  • Gene transfers in cells in culture can be carried out relatively easily using various physical or chemical means.
  • the highest effectiveness is achieved with vectors that are derived from viruses and have been genetically modified in a targeted manner. Retroviruses and adenoviruses have been used particularly successfully.
  • Dividing differentiated hepatocytes are necessary for such tests. Attempts have long been made to establish lines of differentiated hepatocytes in rodents and humans.
  • human hepatocytes were immortalized with the SV40 T-Ag using retroviral infection.
  • the lines THLE-2 and -3 obtained were not tumorigenic in nude mice and did not express AFP.
  • the cells from previous passages were able to produce albumin and cytokeratin 8 (CKN8, characteristic of hepatocytes) and to metabolize a number of chemical carcinogens.
  • the expression of cytokeratin (CKN19, characteristic of bile duct epithelium) and a reduction in albumin expression were observed in cells of later passages (Pfeifer et al., 1993).
  • Two lines of differentiated, immortalized hepatocytes were obtained from transgenic mice that express the gene for the hepatocyte growth factor TGF- ⁇ .
  • the cells of the two lines AML-12 and AML-14 were not tumorigenic in nude mice and expressed mRNA for albumin, a-1-antitrypsin (AAT) and transferrin. However, the expression of the hepatocyte-specific genes decreased with increasing number of passages (Wu et al., 1994).
  • the aim of the invention is to establish a new human liver cell line which can be used for toxicological, physiological and, in particular, gene therapy studies.
  • the object of the invention is to achieve this goal by genetically influencing the cell cycle regulation of human hepatocytes.
  • the cell line starting from primary human hepatocytes, the following steps were carried out according to the invention (which are also generally applicable to liver cells)
  • the expression of the gene p53 was additionally blocked with the aim of avoiding the apoptotic death of the genetically modified primary hepatocytes.
  • This blockade was carried out as follows: The hepatocytes obtained from the liver segment were sown with a cell density of 5 ⁇ 10 5 per 6 cm dish and cultivated for 2 hours with WM E with growth factors and 10% FCS. 2 hours after plating out, the medium was changed with serum-free WM E. HGF (10ng / ml) was added to the medium. HGF levels in serum are known to increase in the first hours after partial liver resection. The peak of DNA synthesis does not take place until 24-48 hours (in different species) after the operation; that is, about 20-40 hours after the start of the HGF effect. It was expected that the peak of DNA synthesis triggered by plating and HGF influence in primary human hepatocytes should also take place in the same period.
  • hepatocytes were transfected using lipofectamine using the following plasmids (in a ratio of 1: 1: 1: 1):
  • hepatocytes were transfected in 5 dishes (total cell number 2.5 ⁇ 10 6 ). Furthermore, 5 hours after the transfection when changing the medium, 10% FCS was also added to the medium (as well as growth factors). 18 days after the transfection, the majority of the transfected cells had degenerated (while the hepatocytes in the control dishes retained their viability for up to 6 weeks). During this period, only 4 colonies were observed in one dish. One of the colonies was transferred to a 24-well plate. Fresh WM E and conditioned supernatant from colonies formed (in a ratio of 1: 1) were added to these cells. The cells grew and after 2 days the number of cells doubled.
  • the morphology of the cells in the center of the colony was very similar to that of primary hepatocytes, while the cells at the edge of the colony were very extended.
  • the cells of the colony had rounded and then peeled off the surface of the dishes, after which cell death was observed.
  • the cells If they are sown as a single cell suspension in low cell density, then they have an extended morphology. After the formation of line-to-line contacts, the cells become polygonal Hepatocyte-like morphology. After confluence, the cells do not form a "three-dimensional foci", but detach from the surface of the shell. This indicates that the cells had not been transformed.
  • HepZ The established hepatocytes were called HepZ.
  • the established cells were analyzed for hepatocyte-specific parameters using immunofluorescence.
  • Primary human hepatocytes (fixed 24 hours after isolation - HuPrimHep) served as controls, and the cells of the human hepatoma lines HepG2 and HuH7. The results are shown in Table 1.
  • Hepatocyte-specific markers of established human hepatocytes (HepZ) in immunofluorescence
  • HepZ (Fig. 3a) as well as HuH7 (Fig. 3b), HepG2 cells (Fig. 3c) and primary hepatocytes (Fig. 3d) are strongly positive for albumin.
  • AAT Alpha-1-Antitrypsin
  • the HepZ were still positive after 3 passages.
  • HepZ are negative for alpha-fetoprotein (AFP) (Fig. 3f). This indicates that the established cells come from differentiated hepatocytes. All cells (including primary human hepatocytes) were positive for both CKN8 and CKN19.
  • the HepZ line was also tested for expression of p53 and pRb.
  • the hepatoma lines mentioned above were used as controls (Table 2).
  • HepG2 and HuH7 cells served as controls.
  • Hepatocyte line HepZ established from primary human hepatocytes using lipofectamine-mediated transfection with a plasmid combination: pAlbasp53 + pAlbas Rb + pCMVE2F + pSV2neoDl (after 15 passages) (enlargement 1: 100)
  • HuH7 and HepG2 hepatoma lines served as controls. a. strong expression of the mutant p53 in HuH7 cells, b.
  • HepZ cells The expression of pRb in d. hepG2, e. HepZ.
  • Lane 1 HepG2 cells
  • Lane 2 HepZ cells
  • Lane 3 HuH7 cells
  • b. p53 expression Lane 1: HuH7 cells
  • Lane 2 HepZ cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une nouvelle lignée cellulaire humaine du foie, pouvant être utilisée pour des recherches toxicologiques, physiologiques et en particulier pour la thérapie génique. La biologie moléculaire, la médecine et l'industrie pharmaceutique constituent des domaines d'application de l'invention. Cette nouvelle lignée cellulaire humaine du foie est caractérisée par les paramètres suivants: albumine: positif, alpha-1-antitrypsine (AAT): positif, et alpha-foetoprotéine (AFP): négatif. Elle est déposée auprès de la Deutsche Sammlung von Mikroorganismen (DSMACC2302).
EP98916819A 1997-03-05 1998-03-03 Lignee cellulaire humaine du foie Withdrawn EP0966522A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19711266A DE19711266C2 (de) 1997-03-05 1997-03-05 Neue humane Leber-Zellinie
DE19711266 1997-03-05
PCT/DE1998/000604 WO1998039417A2 (fr) 1997-03-05 1998-03-03 Lignee cellulaire humaine du foie

Publications (1)

Publication Number Publication Date
EP0966522A1 true EP0966522A1 (fr) 1999-12-29

Family

ID=7823784

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98916819A Withdrawn EP0966522A1 (fr) 1997-03-05 1998-03-03 Lignee cellulaire humaine du foie

Country Status (7)

Country Link
US (1) US6046050A (fr)
EP (1) EP0966522A1 (fr)
JP (1) JP2001523953A (fr)
AU (1) AU7029198A (fr)
CA (1) CA2285677A1 (fr)
DE (1) DE19711266C2 (fr)
WO (1) WO1998039417A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550452A1 (fr) * 2003-10-10 2006-04-20 Multicell Technologies, Inc. Hepatocytes immortalises

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665589A (en) * 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
ES2181677T3 (es) * 1991-08-23 2003-03-01 Univ Nebraska Metodo y composiciones utiles en la reprogramacion celular.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9839417A2 *

Also Published As

Publication number Publication date
US6046050A (en) 2000-04-04
WO1998039417A3 (fr) 1998-12-17
WO1998039417A2 (fr) 1998-09-11
AU7029198A (en) 1998-09-22
DE19711266C2 (de) 1999-06-17
CA2285677A1 (fr) 1998-09-11
JP2001523953A (ja) 2001-11-27
DE19711266A1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
DE69532679T2 (de) Methode zur herstellung einer menschlichen neuralen zelllinie
Villa et al. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS
DE60020855T2 (de) Bedingte immortalisierung von zellen
DE69926639T2 (de) Knochenmarkszellen als quelle von neuronen zur wiederherstellung von gehirn und knochenmark
US7371374B2 (en) Neural transplantation using pluripotent neuroepithelial cells
DE69836139T2 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE68907220T2 (de) Verfahren zur manipulation des zelltyps von eukaryonten.
DE69736858T2 (de) Unsterbliche vogelzellen
DE69725882T2 (de) Adenovirus e4 proteine für induktion von zelltod
DE4407859C1 (de) Vektor für die leberspezifische Gentherapie
DE4322570C1 (de) Stromale Zellinien aus menschlichem Knochenmark
DE19711266C2 (de) Neue humane Leber-Zellinie
Weigel et al. Adenovirus 12S E1A gene represses differentiation of F9 teratocarcinoma cells.
Kuroda Characteristic and selective aggregate-forming activity of neoplastic cells in culture
DE69534873T2 (de) Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren
EP1440085B1 (fr) Immortalisation transitoire de celluses par des proteines oncogeniques ou telomerase
DE69531627T2 (de) Humane hypertrophe chrondrozyten zelllinien
DE19816116C2 (de) Verfahren zur Immortalisation von Zellen mit Hilfe konditional transformierter Helferzellen
WO2001011030A2 (fr) Procede et moyen permettant d'induire la multiplication cellulaire de cellules au repos
WO1993013204A2 (fr) Stimulant de la division de cellules animales
WO1996035797A1 (fr) Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci
DE10259617A1 (de) Verfahren zur Inhibierung des Proliferationspotentials von Zellpopulationen und Geweben
WO1997037015A1 (fr) Proteine a activite inductrice de la differenciation de lignees de cellules d'erythroleucemie de friend
Bernardino-Sgherri et al. 4.6. Complex Relationships Between DNA Methylation Status and Chromosome Compaction and Cohesion
DE19921076A1 (de) Identifizierung eines neuen Tumorsuppressorlocus (NRC-2) in der Chromosomenbande 3p14.2 durch Nachweis einer tumorsupprimierenden und einer seneszenzinduzierenden Aktivität des YAC 145F7-neo

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DK ES FI FR GB IT LI NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KIRILLOWA, IRA

Inventor name: STRAUSS, MICHAEL

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEVELOGEN AKTIENGESELLSCHAFT FUER ENTWICKLUNGSBIOL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021001